Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price rose 12.4% on Wednesday. The company traded as high as GBX 3.50 and last traded at GBX 3.43. Approximately 19,767,809 shares were traded during mid-day trading, an increase of 687% from the average daily volume of 2,511,357 shares. The stock had previously closed at GBX 3.05.
Shield Therapeutics Trading Down 5.2%
The company has a debt-to-equity ratio of -146.28, a quick ratio of 2.16 and a current ratio of 0.75. The company has a market capitalization of £34.63 million, a P/E ratio of -3.22 and a beta of 1.77. The company’s fifty day simple moving average is GBX 5.19 and its 200-day simple moving average is GBX 6.87.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Recommended Stories
- Five stocks we like better than Shield Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
